You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 162 No. 11, June 10, 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (19)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Massive Pulmonary Embolism During Pregnancy Successfully Treated With Recombinant Tissue Plasminogen Activator

A Case Report and Review of Treatment Options

Gregory S. Ahearn, MD; Denis Hadjiliadis, MD; Joseph A. Govert, MD; Victor F. Tapson, MD

Arch Intern Med. 2002;162:1221-1227.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Thromboembolic disease is an important cause of morbidity and mortality during pregnancy.1 Berg and colleagues2 found that 11% of maternal deaths during pregnancy were related to pulmonary embolism (PE). Another study revealed that up to 40% of pregnant women with asymptomatic deep vein thrombosis (DVT) may also have concurrent PE.3 Women are at increased risk for DVT and PE during pregnancy for several reasons. Pregnancy is a thrombophilic state; fibrinogen levels are increased, and during the final trimester there is a decrease in fibrinolytic activity. In addition, the gravid uterus causes compression and stasis in the lower extremities and pelvic veins favoring thrombosis.3 Finally, women with a history of thrombotic complications during pregnancy have an increased prevalence of genetic mutations related to coagulation.4

Traditionally, thromboembolic disease during pregnancy has been treated with unfractionated5 and, more . . . [Full Text of this Article]

REPORT OF A CASE

EMBOLECTOMY

THROMBOLYTIC THERAPY

CATHETER-DIRECTED THROMBOLYTIC THERAPY

VENA CAVA FILTERS

CONCLUSIONS

From the Department of Medicine, Division of Pulmonary and Critical Care, Duke University Medical Center, Durham, NC.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Bates et al.
Chest 2008;133:844S-886S.
ABSTRACT | FULL TEXT  

Stroke in pregnancy and the puerperium
Treadwell et al.
Postgrad. Med. J. 2008;84:238-245.
ABSTRACT | FULL TEXT  

A clinical approach to the management of thrombosis in obstetrics. Part 2: diagnosis and treatment of venous thromboembolism
Asghar and Bowman
The Obstetrician and Gynaecologist 2007;9:3-8.
ABSTRACT | FULL TEXT  

Intravenous Recombinant Tissue Plasminogen Activator in a Pregnant Woman With Cardioembolic Stroke
Wiese et al.
Stroke 2006;37:2168-2169.
ABSTRACT | FULL TEXT  

Thrombolytic Therapy for Acute Stroke in Late Pregnancy With Intra-Arterial Recombinant Tissue Plasminogen Activator
Johnson et al.
Stroke 2005;36:e53-e55.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.